Micelles of TPGS modified apigenin phospholipid complex for oral administration: preparation, in vitro and in vivo...

Mixed micelles were designed to increase oral bioavailability of Apigenin (Ap). The phospholipid (Ph) complex technology was exploited alongside TPGS' stabilizing effect by PEG chain sterical hindrance of the phase II enzymes. This prevented extensive metabolism of Ap while inhibiting P-glycoprotein's exocytosis. TPGS modified micelles of Ap-Ph complex (TPGS-Ap-Ph) were prepared by thin film hydration method. Ap-Ph complex was confirmed by FTIR and NMR spectroscopy while Ap, Ph and TPGS interactions were studied by surface tensiometry. TPGS-Ap-Ph micelles achieved 87.35% drug encapsulation and 12.6% drug loading showing spherical morphology 137.1 +/- 3.4 nm particle size and -12.94 mV surface charge. The negative zeta potential confirmed computer simulation predictions that PEG moieties of TPGS were at micelles surface, while hydrophobic part inserted to the phospholipid hydrophobic core by electrostatic interactions. TPGS-Ap-Ph micelles were found to be stable for more than 90 days after lyophilization. Comparing to free drug, the micelles increased intestinal absorption of Ap 2.4 fold, illustrating apparent permeation (P(app)) and absorption constant (K(a)) of 7.9 x 10(-4) and 2.05 x 10(-4) (p < 0.001) respectively. Moreover, cell culture studies showed high cellular uptake with sufficient intracellular trafficking in A549 cells. MTT assays revealed a significant cytotoxic effect by TPGS-Ap-Ph micelles. In vivo, an effective inhibition of 72.9% was achieved upon oral administration to S180 carcinoma mice compared to 19.5% by Ap-Ph complex. Altogether reflect that orally administered mixed micelles of TPGS-Ap-Ph could effectively inhibit cancer. The results present the designed micelles as a new way to improve oral bioavailability of sparingly soluble and poorly absorbed drugs.